key: cord-0738323-uy02qbv3
authors: De Santis, Gil C.; Calado, Rodrigo T.
title: High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
date: 2022-05-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2805.220363
sha: c350d5fd6c45b3392d98cb2a7c206418a9aa2da1
doc_id: 738323
cord_uid: uy02qbv3

nan

In Response: We thank Focosi and Casadevall for their comments (1) . One strong contribution of our study was the high dose (i.e., 1,800 mL in 3 days) of coronavirus disease (COVID-19) convalescent plasma (CCP), which, in our opinion, would be more likely to benefit patients than a lower dose (e.g., 200-600 mL in 1 or 2 doses), as is the protocol in most CCP studies (including but not limited to COVID-19 treatment) (2) .

The weak point of our study was the relatively large therapeutic window (up to 10 days of signs/ symptoms) for CCP transfusion, which may have included the later inflammatory process of illness. One early trial suggested benefit for COVID-19 patients who received CCP within the first 14 days (3). Nevertheless, subsequent trials showed that CCP (or serum) administration could be most beneficial for COVID-19 patients when administered as prophylaxis or within the first days of infection (4, 5) , ideally, within the first 3 days (6) but perhaps not later (7, 8) .

We emphasize that CCP transfusion was considered experimental at the beginning of the pandemic, and inclusion criteria comprised only patients with severe illness, for whom >7 days of infection are needed for illness to become evident.

We think that applying the suggested formula to identify which COVID-19 patients are likely to benefit from CCP (higher risk for progression to severe disease) would not be applicable to our study because it was envisaged for patients not receiving mechanical ventilation (9) , whereas the patients in our study had severe disease (90% receiving mechanical ventilation).

In summary, our study emphasizes that CCP should not be transfused late in the course of disease, when the clinical course is driven by inflammation. This conclusion does not exclude the possibility of transfusing CCP as soon as patients are identified for potential benefit, as suggested by other studies (6, 7) . 

High-dose convalescent plasma for treatment of severe COVID-19

Association of convalescent plasma treatment with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19 in the community setting

COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes

Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma

References 1. Focosi D, Casadevall A. High-dose convalescent plasma for treatment of severe COVID-19

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Use of convalescent plasma therapy in SARS patients in Hong Kong

COVID-19 convalescent plasma is more than neutralizing antibodies: a narrative review of potential beneficial and detrimental co-factors

Serum therapy revisited: animal models of infection and development of passive antibody therapy

Early high-titer plasma therapy to prevent severe Covid-19 in older adults

SIREN-C3PO Investigators. Early convalescent plasma for high-risk outpatients with Covid-19

PlasmAr Study Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia

Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma